DOSTARLIMAB

Brand name:

• Jemperli®

Pharmaceutical company:

GlaxoSmithKline Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Endometrial cancer

PBAC Submission type:

Change to listing (Standard Re-entry Pathway)

Comment:

--

Related medicines:

• DOSTARLIMAB

Submission received for:

March 2023 PBAC meeting

Opportunity for consumer comment:

Open 23/11/2022 and close 25/01/2023 (see PBS Website)

PBAC meeting:

Held on 08/03/2023

PBAC outcome published:

Not Applicable (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---